Comparison · NCT04533737-8e9b8de2
Arm 1 (Brodalumab + Dummy 1) vs Arm 2 (Guselkumab + Dummy 2): Occurrence of Treatment-emergent Adverse Events (AEs) From Baseline to Week 28.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm 1 (Brodalumab + Dummy 1) vs Arm 2 (Guselkumab + Dummy 2): Occurrence of Treatment-emergent Adverse Events (AEs) From Baseline to Week 28. Trial comparisons, record NCT04533737-8e9b8de2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04533737-8e9b8de2
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.75 | 0.623 | 0.845 | wilson | |
| Risk in group 2 | 0.554 | 0.424 | 0.676 | wilson | |
| Risk difference, group 1 minus group 2 | 0.196 | 0.02 | 0.357 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.35 | 1.02 | 1.79 | log | |
| Odds ratio, group 1 over group 2 | 2.42 | 1.08 | 5.4 | log | |
| Number needed to treat, for one more participant with the outcome on Arm 1 (Brodalumab + Dummy 1) than on Arm 2 (Guselkumab + Dummy 2) | 5.09 | 2.8 | 50 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm 1 (Brodalumab + Dummy 1) | Participants receive:~* Brodalumab 210 mg (1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks.~* Dummy 1 (placebo 1.0 ml) at Weeks 0, 4, and then every 8 weeks.~Brodalumab: Pre-filled syringe with 210 mg brodalumab in 1.5 ml solution for subcutaneous injection.~Placebo: The placebo solution is similar to the active guselkumab solution except that it does not contain any active substance. | 42 | 56 | OG000 |
| Group 2 | Arm 2 (Guselkumab + Dummy 2) | Participants receive:~* Guselkumab 100 mg (1.0 ml) at Weeks 0, 4, and then every 8 weeks.~* Dummy 2 (placebo 1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks.~Guselkumab: Pre-filled syringe with 100 mg guselkumab in 1 ml solution for subcutaneous injection.~Placebo: The placebo solution is similar to the active brodalumab solution except that it does not contain any active substance. | 31 | 56 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Occurrence of Treatment-emergent Adverse Events (AEs) From Baseline to Week 28.
- Description
An adverse event is considered treatment-emergent if the onset occurred after the first administration of IMP or if the event started prior to the first administration of IMP and worsened in severity after the first administration of IMP.
- Time frame
- From baseline to Week 28
- Population
- Safety analysis set
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
- NCT number
- NCT04533737
- Phases
- PHASE4
- Conditions
- Plaque Psoriasis, Psoriasis Vulgaris, Psoriasis
- Interventions
- Brodalumab, Placebo, Guselkumab
- Lead sponsor
- LEO Pharma
- Results first posted
- 2024-01-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04533737?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04533737-8e9b8de2